Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1944 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-1944 | EXPERIMENTAL | Escalating dose levels |
| Placebo | PLACEBO_COMPARATOR | Saline |
| Name | Type | Description |
|---|---|---|
| mRNA-1944 | BIOLOGICAL | mRNA encoding Chikungunya antibody |
| Placebo | OTHER | Saline |
Inclusion Criteria: * Male or female ≥ 18 and ≤ 50 years of age * Weight of 50 to 100 kg, inclusive * In good general health as determined by medical history, clinical laboratory assessments, ECG results, vital sign measurements, and physical examination findings at screening * Has access to consis...
mRNA-1944 is an investigational vaccine being developed by Moderna, Inc. for the prevention of Chikungunya virus infection. It is an mRNA-based vaccine candidate that has been studied in a single Phase 1 clinical trial in healthy adult volunteers in the United States.
mRNA-1944 is being developed for the prevention of Chikungunya virus infection, an infectious disease. It is an investigational vaccine candidate and has not been approved for use. Its only clinical study enrolled healthy adult volunteers rather than people with an active infection.
mRNA-1944 is being developed by Moderna, Inc., which trades on the Nasdaq under the ticker symbol MRNA. Moderna is the sponsor of the clinical program for this mRNA-based vaccine candidate targeting prevention of Chikungunya virus infection.
mRNA-1944 is in Phase 1 development. Its single clinical trial, NCT03829384, has been completed. The study was a randomized, double-blind, placebo-controlled Phase 1 trial that enrolled 39 healthy adult volunteers aged 18 years and older in the United States.
mRNA-1944 has been studied in one clinical trial, NCT03829384, titled Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults. The Phase 1 trial enrolled 39 participants in the United States, used a randomized, double-blind, placebo-controlled design, and is now completed.